F-1/A: Polyrizon Ltd. Files for IPO to Advance Nasal Spray Medical Devices

Polyrizon Ltd. files an amendment to its F-1 registration statement, outlining its plans for an initial public offering to further develop its nasal spray medical devices targeting allergies and viral infections.

Summary

• Polyrizon Ltd., a biotech company specializing in nasal spray medical devices, has filed Amendment No. 12 to its Form F-1 registration statement.
• The company is planning an initial public offering (IPO) involving units consisting of ordinary shares and warrants, as well as pre-funded units.
• The IPO aims to raise funds for the development of its Capture and Contain (C&C) technology, including PL-14 (nasal allergy blocker), PL-15 (COVID-19 blocker), and PL-16 (influenza blocker) product candidates.
• The company is also developing Trap and Target (T&T) technology for nasal delivery of active pharmaceutical ingredients (APIs).
• Polyrizon has applied to list its Ordinary Shares on The Nasdaq Capital Market under the symbol PLRZ.
• The company has granted the underwriter an option to purchase additional Ordinary Shares and/or Warrants and/or Pre-Funded Warrants within 45 days from the date of this prospectus to cover over-allotments, if any.
• Certain existing shareholders have indicated an interest in purchasing up to an aggregate of $1 million of Units in this offering.

Sentiment

Score: 6

Explanation: The document presents a balanced view. While it highlights the company's potential and plans, it also acknowledges the significant risks and challenges associated with its business, financial condition, and the regulatory approval process. The sentiment is neutral, reflecting the inherent uncertainties in the biotech industry.

Positives

• The company's C&C technology has shown promising results in in-vitro studies, demonstrating a barrier effect against viruses and allergens.
• The company has a Scientific Advisory Board of professors with expertise in drug delivery systems, chemistry and pharmaceuticals.
• The company has an exclusive patent license agreement with SciSparc for the SCI-160 platform, potentially expanding its product pipeline.
• The company has a collaboration agreement with NurExone Biologic Inc. to develop formulations for intranasal delivery of ExoTherapy for spinal cord injuries.
• The company is pursuing established regulatory pathways (510(k) and De Novo) for its C&C product candidates, which could streamline the approval process.

Negatives

• The company has incurred significant losses since its inception and expects to continue incurring losses for the foreseeable future.
• The company has never generated any revenue from product candidates sales and may never be profitable.
• The company will need to raise substantial additional funding, which may not be available on acceptable terms, or at all.
• The company is heavily dependent on the success of its C&C product candidates.
• The company has not previously conducted pivotal clinical trials.
• The company does not plan to conduct a pre-submission meeting with the FDAs CDRH to confirm the potential for the Class II medical device path under a de novo classification request for its PL-15 and PL-16 products until after the completion of this initial public offering.

Risks

• The company's financial statements contain an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern.
• The company depends on enrollment of patients in its upcoming clinical trials in order to continue development of our product candidates.
• The company may not receive, or may be delayed in receiving, the necessary clearances or approvals for its product candidates.
• The company faces intense competition in an environment of rapid technological change.
• The company's headquarters and other significant operations are located in Israel, and, therefore, its results may be adversely affected by political, economic and military instability in Israel, including the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israels war against them.

Future Outlook

The company expects its expenses and operating losses to increase for the foreseeable future as it continues clinical development of its C&C product candidates and develops other product candidates using its T&T platform technology.

Industry Context

The company operates in the competitive pharmaceutical and medical device industry, focusing on nasal drug delivery systems. The market for nasal sprays is expected to grow significantly, driven by rising infections, allergic conditions, and the convenience of nasal administration.

Comparison to Industry Standards

• The FDA submission and clearance process for Alzair Allergy Blocker took 86 days.
• The FDA submission and clearance process for NASAL EASE ALLERGY BLOCKER took 140 days.

Related Party Transactions

• The company has entered into a series of securities purchase agreements with certain of its principal shareholders, including XYLO, Raul Srugo, Itzhak Srugo, Yoav Srugo and Sofi Yochelman Srugo, pursuant to which we issued an aggregate of 513,878 Ordinary Shares for gross proceeds of $582,000.
• On February 4, 2023, the company entered into a convertible loan agreement with Reuven Srugo Construction Company Ltd., or Reuven Construction and XYLO, pursuant to which Reuven Construction and XYLO extended a loan the Company in the principal amount of $180,000, with an annual interest rate of approximately 4%.
• On July 15, 2020, we entered into a share purchase agreement with XYLO, pursuant to which we issued a total of 43,964 of our Ordinary Shares, at a price per share of $2.36 for aggregate gross proceeds of $104,000.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new shares and warrants.
• Employees: Potential for increased job opportunities and career growth as the company expands.
• Customers: Access to innovative nasal spray medical devices for allergies and viral infections.
• Suppliers: Increased demand for raw materials and manufacturing services.
• Creditors: Repayment of existing convertible loans.

Next Steps

• Complete preclinical development for PL-14, PL-15, and PL-16 product candidates.
• Complete clinical development for PL-14 product candidate.
• Complete in vitro feasibility studies of corticosteroid, benzodiazepine, naloxone for T&T platform technology product candidates.
• Repay the April 2024 CLA and August 2024 CLA.
• Initiate preclinical safety trials for PL-14, PL-15, and PL-16 product candidates in the second quarter of 2025.
• Commence pivotal clinical trial for PL-14 product candidate in the fourth quarter of 2025.
• Initiate feasibility clinical trials for PL-16 product candidate in the first quarter of 2026, subject to securing additional financing.
• Begin pre-clinical studies for T&T platform product candidates in the second quarter of 2026.
• Initiate feasibility clinical trials for PL-15 product candidate in the third quarter of 2026, subject to securing additional financing.
• Initiate pivotal clinical trials for PL-16 product candidate in the third quarter of 2026, subject to securing additional financing.
• Initiate pivotal clinical trials for PL-15 product candidate in the second quarter of 2027, subject to securing additional financing.
• Plan Phase I clinical trials for the leading T&T technology product candidate for the fourth quarter of 2027, subject to securing additional financing.

Key Dates

Keywords

nasal spray, medical device, IPO, Polyrizon, hydrogel, allergies, COVID-19, influenza, pharmaceutical, biotech